E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.

"Competing interests MS has consulted for Curis Oncology, Boston Consulting and is member of the advisory board for Novartis and Kymera. OA-W has served as a consultant for H3B Biomedicine, Foundation Medicine Inc, Merck, Prelude Therapeutics, and Janssen, and is on the Scientific Advisory Board of Envisagenics Inc., AIChemy, Harmonic Discovery Inc., and Pfizer Boulder; OA-W has received prior research funding from H3B Biomedicine, Nurix, Minovia, and LOXO Oncology unrelated to the current manuscript. EMS received research funding from Bayer; was a consultant for Amgen, AbbVie, Seattle Genetics, and Biotheryx; served as a consultant and received research funding from Syndax; was a member of the Board of Directors or advisory committee for PTC Therapeutics and Syros; served as a consultant and was member of the Board of Directors or advisory committee for Astellas Pharmaceutical, Agios Pharmaceuticals, and Genentech; served as a consultant, received research funding, and was a member of the Board of Directors or advisory committee for Daiichi-Sankyo, Celgene Pharmaceuticals, and Novartis; and is a current equity holder in privately held Auron Therapeutics. None of these relationships were related to the development of this manuscript. The remaining authors declare no competing financial interests."

"This study was supported by Eisai Pharmaceuticals, the Leukemia & Lymphoma Society, and the Rising Tide Foundation for Clinical Cancer Research. O.A.-W. is supported in part by the Edward P. Evans Foundation, NIH/NCI (R01 CA251138 and R01 CA242020), NIH/NHLBI (R01 HL128239), the Rising Tide Foundation for Clinical Cancer Research, and the Leukemia & Lymphoma Society. OA-W and ES are supported by NIH/NCI P50 CA254838-01."